Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RIGLNASDAQ:SNSSNASDAQ:VSTMNASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRIGLRigel Pharmaceuticals$18.72-4.3%$18.97$7.48▼$29.82$334.47M1.32208,174 shs152,066 shsSNSSSunesis Pharmaceuticals$3.53$1.12▼$11.30$96.26M2.274.33 million shs1.20 million shsVSTMVerastem$7.43-0.8%$6.19$2.10▼$13.52$385.66M0.571.03 million shs1.06 million shsXOMAXOMA$23.44-2.5%$21.27$18.35▼$35.00$280.18M128,056 shs31,698 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRIGLRigel Pharmaceuticals-0.05%+7.71%+8.73%-13.45%+86.29%SNSSSunesis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VSTMVerastem+7.46%+4.39%+24.21%+20.42%-24.95%XOMAXOMA-1.39%+3.00%+20.62%-8.45%-5.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRIGLRigel Pharmaceuticals2.7516 of 5 stars3.21.00.00.02.82.51.9SNSSSunesis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVSTMVerastem3.2107 of 5 stars4.51.00.00.03.22.50.6XOMAXOMA4.0329 of 5 stars3.52.00.03.02.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRIGLRigel Pharmaceuticals 2.40Hold$36.8096.58% UpsideSNSSSunesis Pharmaceuticals 0.00N/AN/AN/AVSTMVerastem 3.00Buy$13.8986.93% UpsideXOMAXOMA 3.00Buy$69.50196.50% UpsideCurrent Analyst Ratings BreakdownLatest SNSS, VSTM, RIGL, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025XOMAXOMABenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.003/28/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.003/24/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/21/2025VSTMVerastemRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.003/19/2025XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/6/2025RIGLRigel PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $55.003/5/2025RIGLRigel PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.003/5/2025RIGLRigel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRIGLRigel Pharmaceuticals$179.28M1.87N/AN/A($1.64) per share-11.41SNSSSunesis Pharmaceuticals$2.07M0.00N/AN/A$1.42 per share0.00VSTMVerastem$10M38.26N/AN/A$2.27 per share3.27XOMAXOMA$10.22M27.41N/AN/A$7.72 per share3.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRIGLRigel Pharmaceuticals-$25.09M$0.94133.7217.83N/A2.46%-14.80%3.03%5/6/2025 (Estimated)SNSSSunesis Pharmaceuticals-$23.33M-$2.70N/AN/AN/AN/A-179.05%-72.27%N/AVSTMVerastem-$87.37M-$3.50N/AN/AN/AN/A-332.73%-73.97%5/8/2025 (Estimated)XOMAXOMA-$40.83M-$2.07N/AN/AN/A-151.34%-24.95%-9.64%5/8/2025 (Estimated)Latest SNSS, VSTM, RIGL, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025VSTMVerastem-$0.65N/AN/AN/A$0.10 millionN/A5/8/2025Q1 2025XOMAXOMA-$0.26N/AN/AN/A$6.75 millionN/A5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14N/AN/AN/A$43.87 millionN/A3/20/2025Q4 2024VSTMVerastem-$0.76-$1.33-$0.57-$1.33$0.15 millionN/A3/17/2025Q4 2024XOMAXOMA-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 million3/4/2025Q4 2024RIGLRigel Pharmaceuticals$0.30$0.80+$0.50$0.80$57.59 million$57.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ASNSSSunesis PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRIGLRigel PharmaceuticalsN/A1.961.87SNSSSunesis PharmaceuticalsN/A7.747.74VSTMVerastem2.773.233.23XOMAXOMA1.287.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRIGLRigel Pharmaceuticals66.23%SNSSSunesis Pharmaceuticals28.41%VSTMVerastem88.37%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipRIGLRigel Pharmaceuticals9.04%SNSSSunesis Pharmaceuticals4.22%VSTMVerastem2.10%XOMAXOMA7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRIGLRigel Pharmaceuticals16017.87 million16.02 millionOptionableSNSSSunesis Pharmaceuticals2418.09 millionN/AOptionableVSTMVerastem5051.49 million43.53 millionOptionableXOMAXOMA1011.95 million10.94 millionOptionableSNSS, VSTM, RIGL, and XOMA HeadlinesRecent News About These CompaniesHigh Growth Tech Stocks In The US To Watch April 2025April 22, 2025 | uk.finance.yahoo.comXOMA (NASDAQ:XOMA) Now Covered by BenchmarkApril 19, 2025 | marketbeat.comBenchmark Initiates Coverage of XOMA Royalty Corporation - Preferred Stock (XOMAP) with Buy RecommendationApril 18, 2025 | msn.comXoma initiated with a Buy at BenchmarkApril 17, 2025 | markets.businessinsider.comXoma (XOMA) Receives Buy Rating from Benchmark with Promising Growth Forecast | XOMA Stock NewsApril 17, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | gurufocus.comXOMA (XOMA) Sells Kinnate Biopharma Pipeline Assets for Potential $270M | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline Assets | XOMA Stock NewsApril 14, 2025 | gurufocus.comXOMA Royalty Completes Sale of Kinnate Pipeline AssetsApril 14, 2025 | globenewswire.comXOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.comApril 13, 2025 | marketbeat.comInsider Buying: XOMA Co. (NASDAQ:XOMA) CIO Purchases 2,000 Shares of StockApril 10, 2025 | insidertrades.comXOMA Royalty Corporation (XOMA): Among Stocks Insiders Bought in April After Trump’s Tariff RolloutApril 9, 2025 | msn.comJoseph M. Limber Buys 5,243 Shares of XOMA Co. (NASDAQ:XOMA) StockApril 9, 2025 | insidertrades.comInsider Buying: XOMA Co. (NASDAQ:XOMA) Director Acquires 5,243 Shares of StockApril 9, 2025 | marketbeat.comXOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber Buys 17,935 SharesApril 9, 2025 | marketbeat.comBioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3April 8, 2025 | accessnewswire.comXOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech TwistApril 8, 2025 | seekingalpha.comXOMA (NASDAQ:XOMA) Rating Lowered to "Sell" at StockNews.comApril 5, 2025 | marketbeat.comXOMA Royalty to Present at Jones Healthcare and Technology Innovation ConferenceApril 2, 2025 | globenewswire.comBradley Sitko Acquires 4,134 Shares of XOMA Co. (NASDAQ:XOMA) StockMarch 26, 2025 | insidertrades.comInsider Purchase: Chief Investment Officer of $XOMA Buys 2,800 SharesMarch 25, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNSS, VSTM, RIGL, and XOMA Company DescriptionsRigel Pharmaceuticals NASDAQ:RIGL$18.72 -0.84 (-4.29%) Closing price 04:00 PM EasternExtended Trading$18.65 -0.07 (-0.37%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Sunesis Pharmaceuticals NASDAQ:SNSSSunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.Verastem NASDAQ:VSTM$7.43 -0.06 (-0.80%) Closing price 04:00 PM EasternExtended Trading$7.38 -0.04 (-0.61%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.XOMA NASDAQ:XOMA$23.44 -0.60 (-2.50%) Closing price 04:00 PM EasternExtended Trading$23.54 +0.09 (+0.41%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
